[go: up one dir, main page]

WO2024006841A3 - Compositions pour la perte de poids et le traitement du cancer - Google Patents

Compositions pour la perte de poids et le traitement du cancer Download PDF

Info

Publication number
WO2024006841A3
WO2024006841A3 PCT/US2023/069273 US2023069273W WO2024006841A3 WO 2024006841 A3 WO2024006841 A3 WO 2024006841A3 US 2023069273 W US2023069273 W US 2023069273W WO 2024006841 A3 WO2024006841 A3 WO 2024006841A3
Authority
WO
WIPO (PCT)
Prior art keywords
disclosed
compositions
disorders
weight loss
cancer treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/069273
Other languages
English (en)
Other versions
WO2024006841A2 (fr
Inventor
James M. Sonner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Knowledge Pharmaceuticals Inc
Original Assignee
Knowledge Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knowledge Pharmaceuticals Inc filed Critical Knowledge Pharmaceuticals Inc
Publication of WO2024006841A2 publication Critical patent/WO2024006841A2/fr
Publication of WO2024006841A3 publication Critical patent/WO2024006841A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La divulgation concerne, entre autres, des méthodes d'induction d'anesthésie et de sédation et des méthodes de traitement de maladies et de troubles comprenant des troubles du système nerveux central, des lésions cérébrales traumatiques, des troubles du système nerveux périphérique, l'obésité, le cancer, la dépression et l'ischémie. La divulgation concerne également des traitements à l'aide d'un anticonvulsivant contre des maladies et des troubles. Des traitements peuvent consister à administrer une dose efficace d'un composé ou d'une formulation selon la divulgation à un sujet en ayant besoin. La divulgation concerne également des compositions comprenant de l'acide bêta-hydroxybutyrique (BHB) pour le traitement de cancers et de l'obésité.
PCT/US2023/069273 2022-06-29 2023-06-28 Compositions pour la perte de poids et le traitement du cancer Ceased WO2024006841A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263356523P 2022-06-29 2022-06-29
US63/356,523 2022-06-29
US202363455032P 2023-03-28 2023-03-28
US63/455,032 2023-03-28

Publications (2)

Publication Number Publication Date
WO2024006841A2 WO2024006841A2 (fr) 2024-01-04
WO2024006841A3 true WO2024006841A3 (fr) 2024-02-22

Family

ID=89381704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/069273 Ceased WO2024006841A2 (fr) 2022-06-29 2023-06-28 Compositions pour la perte de poids et le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2024006841A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137236A1 (en) * 2007-05-15 2010-06-03 Medical College Of Georgia Research Institute, Inc Georgia Compositions Comprising a GPR109 Ligand For Treating Disorders of the Digestive Tract and/or Cancer
US20180021274A1 (en) * 2016-07-21 2018-01-25 Savind, Inc. Compositions comprising beta-hydroxybutyric acid and salt, and methods of using the same
US20180134703A1 (en) * 2016-10-10 2018-05-17 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US20210402199A1 (en) * 2018-11-13 2021-12-30 The Methodist Hospital Method and apparatus for oncomagnetic treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137236A1 (en) * 2007-05-15 2010-06-03 Medical College Of Georgia Research Institute, Inc Georgia Compositions Comprising a GPR109 Ligand For Treating Disorders of the Digestive Tract and/or Cancer
US20180021274A1 (en) * 2016-07-21 2018-01-25 Savind, Inc. Compositions comprising beta-hydroxybutyric acid and salt, and methods of using the same
US20180134703A1 (en) * 2016-10-10 2018-05-17 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US20210402199A1 (en) * 2018-11-13 2021-12-30 The Methodist Hospital Method and apparatus for oncomagnetic treatment

Also Published As

Publication number Publication date
WO2024006841A2 (fr) 2024-01-04

Similar Documents

Publication Publication Date Title
US4997853A (en) Method and compositions utilizing capsaicin as an external analgesic
JP5148271B2 (ja) 疼痛処置のためのカプサイシノイド、局所麻酔薬および／または鎮痒薬を含有する処方物
US12036206B2 (en) Compositions and methods for pain relief
GB2596849A (en) Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual
CN1838885A (zh) 治疗皮肤的疮和损害的方法
US20250228906A1 (en) Aqueous liquid extract of Spirulina for the prevention and/or treatment of chemically induced peripheral neuropathy and their symptoms, composition and use thereof
DE69812100T2 (de) Adenosin enthaltendes arzneimittel
WO2024006841A3 (fr) Compositions pour la perte de poids et le traitement du cancer
JP2004523553A (ja) 疼痛（ｐａｉｎ）の治療における使用のためのカルバメート化合物
WO2022234064A1 (fr) Capsaïcinoïdes topiques destinés au traitement d'une affection neuropathique chez des patients atteints de covid-19
FI3761982T3 (fi) Nalfurafiinin käyttö demyelinisoivien sairauksien hoidossa
WO2025080877A3 (fr) Peptides thérapeutiques
EP0885013B1 (fr) Utilisation d'inducteurs para-immunitaires obtenus a partir de poxvirus et parapoxvirus attenues non immunogenes pour la preparation de medicaments
AU2024215777A1 (en) Novel compounds that can be used as therapeutic agents
AU2024210779A1 (en) Compositions and formulations for the prevention, treatment, and improvement of skin diseases, conditions, and disorders
ES2268053T3 (es) Uso de acetil l-carnitina en asociacion con biotina para el tratamiento de pacientes con diabetes mellitus de tipo 2 resistente a insulina.
WO2023158955A3 (fr) COMPOSITIONS DE 3α-OH-5β-PRÉGNAN-20-ONE ET MÉTHODES DE TRAITEMENT DE TROUBLES DU SYSTEME NERVEUX CENTRAL
WO2019030772A1 (fr) Formulation à base d'huile pour la prise en charge d'une guérison/douleur
Pages et al. Severe sensorimotor neuropathy after cisplatin therapy
MX2015003879A (es) Metodos para aliviar sintomas de esclerosis multiple basados en composiciones que contienen apoaecuorina.
WO2020168337A4 (fr) Compositions et méthodes pour le traitement de la dépression et d'autres troubles
CN114073698B (zh) 一种止痛止痒药物组合物及其应用方法
US20250152505A1 (en) Spray compositions and methods of use
RU2189820C1 (ru) Способ лечения бронхиальной астмы
Shavlovskaya Efficacy of Recognan in the therapy of neurological disorders after traumatic brain injury

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23832551

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23832551

Country of ref document: EP

Kind code of ref document: A2